Home › Metastatic Cancer › New York › New York City
Metastatic Cancer clinical trials in New York City, NY
93 studies for Metastatic Cancer are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, New York
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPhase 3
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
RecruitingPhase 3
- Research Site, New York
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of ASP3082 in Adults With Advanced Solid Tumors
RecruitingPhase 1
- Columbia University - Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- Icahan School of Medicine at Mount Sinai, New York
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, New York
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RecruitingPhase 2/3
- Icahn School of Medicine at Mount Sinai, New York
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
RecruitingPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
SLV-154 Treatment of Advanced Cancers
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
- NYC Health + Hospitals / Bellevue, New York
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RecruitingPhase 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- and 1 more
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center ( Site 0006), New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
RecruitingPhase 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Clinical Study Site, New York
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Manhattan Eye, Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, New York
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- Manhattan Hematology /Oncology Associates, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY), New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Recruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- New York University (NYU), New York
- Weill Cornell Medicine, New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
Decision Support Tool for Patients With Advanced Breast Cancer
Recruiting
- NewYork-Presbyterian David H. Koch Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
RecruitingHealthy volunteers welcome
- NYP/Weill Cornell Medical Center, New York
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RecruitingPhase 1/2
- Crinetics Study Site, New York
A Study of ASP1002 in Adults for Treatment of Solid Tumors
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Investigative Site #103, New York
- Investigative Site #106, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecruitingPhase 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- NYU Langone Health-Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics, New York
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
RecruitingPhase 1
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PYX-201 in Advanced Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- New York Cancer & Blood Specialists (NYCBS), New York
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #7, New York
A Study of LY4175408 in Participants With Advanced Cancer
RecruitingPhase 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
RecruitingPhase 2
- VA New York Harbor Healthcare System, New York
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, New York
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecruitingPhase 1
- Research Site, New York
- Research Site, New York
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
RecruitingObservational study
- Columbia University Irving Medical Center, New York
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RecruitingPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RecruitingPhase 3
- Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
Recruiting
- New York City Health and Hospitals, New York
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York
New MRI Biomarkers in Head and Neck Cancers
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center, New York
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
RecruitingPhase 1/2Healthy volunteers welcome
- Mount Sinai Beth Israel, New York
- Mount Sinai - West, New York
- Dubin breast Center, New York
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- Manhattan Eye, Ear & Throat Hospital, New York
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- Memorial Sloan Kettering Cancer Center, New York
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Centre, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RecruitingObservational study
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
RecruitingPhase 1/2
- Columbia University Irving Medical Center, New York
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
RecruitingPhase 3
- Memorial Sloan Kettering Cancer Center, New York
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RecruitingPhase 1
- Ichan School of Medicine at Mount Sinai, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
Comprehensive Outcomes for After Cancer Health
RecruitingHealthy volunteers welcome
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecruitingPhase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
- Seattle, WA39 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
- Heart Failure51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.